Search - tctmd.com

Displaying 781 - 800 of 2221

Sort: Relevancy | Date

Presentation TCT 2015

Transcatheter Mitral Therapies in 2015: MitraClip in Trials and the Real World

Presenter: Blase A. Carabello, Howard C. Herrmann, Ted E. Feldman

October 12, 2015

Presentation TCT 2015

What Will TAVR Look Like in 2 and 10 Years From Now?

Presenter: Blase A. Carabello, Howard C. Herrmann, Duane S. Pinto

October 12, 2015

Presentation TCT 2015

TAVR 2015: Current Status

Presenter: Blase A. Carabello, Howard C. Herrmann, James B. Hermiller Jr

October 12, 2015

Presentation TCT 2015

Guideline Update: Whats New, and Whats Left Unsaid?

Presenter: Blase A. Carabello, Howard C. Herrmann

October 12, 2015

Presentation TCT 2015

Valvular Heart Disease: Aortic Valvuloplasty and TAVR

Presenter: Zoltan G. Turi, Rahul Sakhuja

October 12, 2015

Presentation TCT 2015

The Netherlands Presents: A Case Demonstration of Coronary Flow Capacity to Document Ischemic Heart Disease

Presenter: Morton J. Kern, Jan J. Piek, Tim P. van de Hoef

October 12, 2015

Presentation TCT 2015

Valvular Heart Disease: Treatment of Mitral Stenosis and Mitral Regurgitation

Presenter: Michael J. Lim, Molly Szerlip

October 12, 2015

News Conference News TCT 2015

Experts Debate Mitral Valve Repair, Replacement for Intermediate-Risk Patients

October 12, 2015

News Conference News TCT 2015

CoreValve Extreme Risk Pivotal Trial: Improved Benefits Confirmed After 3 Years

October 12, 2015

News Conference News TCT 2015

ABSORB III: Novel Bioresorbable Scaffold as Good as Standard-of-Care DES

Yael L. Maxwell

October 12, 2015

News Industry News

ABSORB III: Clinical Trial Demonstrates That A Bioresorbable Scaffold Is Non-Inferior To A Drug-Eluting Stent In Patients With Coronary Artery Disease

October 12, 2015

News Industry News

St. Jude Medical Announces CE Mark Approval for the HeartMate 3 Left Ventricular Assist System

October 12, 2015

News Conference News TCT 2015

Boston Scientific Co-founder John Abele Recognized by TCT Career Achievement Award

October 12, 2015

Presentation TCT 2015

PCI for Multivessel Disease in the CABG Candidate: Should We Follow the Guidelines? With Case Examples

Presenter: Thomas Engstroem, Manh-Hung Pham, Nhan Thanh Vo, Minh Vo

October 11, 2015

Presentation TCT 2015

PCI for Multivessel Disease With CTO: When and How? With Case Examples

Presenter: Thomas Engstroem, Manh-Hung Pham, Nhan Thanh Vo, Cheol Woong Yu

October 11, 2015

Presentation TCT 2015

Debate: Should Most Patients With Stable Ischemic Heart Disease, Moderate or Greater Ischemia, and Controllable Symptoms Undergo Revascularization? Yes, an Evidence-Based Position!

Presenter: Kevin J. Beatt, Craig R. Smith, Gregg W. Stone

October 11, 2015

Presentation TCT 2015

A Practical Stenting Issue in Multivessel Disease: When and Where to Stop? With Case Examples

Presenter: Thomas Engstroem, Manh-Hung Pham, Nhan Thanh Vo, Kevin Bainey

October 11, 2015

Presentation TCT 2015

Debate: Should Most Patients With Stable Ischemic Heart Disease, Moderate or Greater Ischemia, and Controllable Symptoms Undergo Revascularization? The Data Says Not as a First-Line Therapy!

Presenter: Kevin J. Beatt, Craig R. Smith, David J. Maron

October 11, 2015

Presentation TCT 2015

How to Apply Physiology-Guided PCI for MVD

Presenter: Thomas Engstroem, Manh-Hung Pham, Chang-Wook Nam

October 11, 2015

Presentation TCT 2015

One-Stage vs Delayed PCI for Nonculprit Lesion in Patients With AMI and Multivessel Disease

Presenter: Thomas Engstroem, Manh-Hung Pham, Henning Kelbæk

October 11, 2015

Advertisement

Transcatheter Mitral Therapies in 2015: MitraClip in Trials and the Real World

What Will TAVR Look Like in 2 and 10 Years From Now?

TAVR 2015: Current Status

Guideline Update: Whats New, and Whats Left Unsaid?

Valvular Heart Disease: Aortic Valvuloplasty and TAVR

The Netherlands Presents: A Case Demonstration of Coronary Flow Capacity to Document Ischemic Heart Disease

Valvular Heart Disease: Treatment of Mitral Stenosis and Mitral Regurgitation

Experts Debate Mitral Valve Repair, Replacement for Intermediate-Risk Patients

CoreValve Extreme Risk Pivotal Trial: Improved Benefits Confirmed After 3 Years

ABSORB III: Novel Bioresorbable Scaffold as Good as Standard-of-Care DES

ABSORB III: Clinical Trial Demonstrates That A Bioresorbable Scaffold Is Non-Inferior To A Drug-Eluting Stent In Patients With Coronary Artery Disease

St. Jude Medical Announces CE Mark Approval for the HeartMate 3 Left Ventricular Assist System

Boston Scientific Co-founder John Abele Recognized by TCT Career Achievement Award

PCI for Multivessel Disease in the CABG Candidate: Should We Follow the Guidelines? With Case Examples

PCI for Multivessel Disease With CTO: When and How? With Case Examples

Debate: Should Most Patients With Stable Ischemic Heart Disease, Moderate or Greater Ischemia, and Controllable Symptoms Undergo Revascularization? Yes, an Evidence-Based Position!

A Practical Stenting Issue in Multivessel Disease: When and Where to Stop? With Case Examples

Debate: Should Most Patients With Stable Ischemic Heart Disease, Moderate or Greater Ischemia, and Controllable Symptoms Undergo Revascularization? The Data Says Not as a First-Line Therapy!

How to Apply Physiology-Guided PCI for MVD

One-Stage vs Delayed PCI for Nonculprit Lesion in Patients With AMI and Multivessel Disease

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content